Gold Standard Diagnostics Launches AIX1000® 2.1 with Extra High Titer RPR Testing

October 22, 2025

 

Davis, CA — October 22, 2025 — Gold Standard Diagnostics is proud to announce the release of AIX1000® Version 2.1, a major upgrade to its flagship RPR automation platform. This release introduces extra high titer capability, now supporting screens and titers up to 1:2048, a breakthrough in syphilis detection and treatment monitoring—especially for late-stage and Neurosyphilis cases.  

The expanded titer range empowers laboratories to more accurately track antibody levels over time, improving clinical decision-making and supporting public health initiatives focused on syphilis control and eradication.  

 “Extra high titer testing is vital for improving detection of late-stage or Neurosyphilis cases, tracking the effectiveness of syphilis treatment over time, and supporting public health,” said Sean Hoesterey, Vice President of Commercial Operations, at Gold Standard Diagnostics.  

 In addition to the enhanced titer range, AIX1000® 2.1 delivers a suite of workflow and data management improvements designed to streamline operations and improve clarity:  

  • Reflex Runs After Worklist Completion 

  • Automatic Next Actions 

  • Improved LIS Communication – Easier for LIS systems to interpret run data  

  • Enhanced Data Analysis 

  • Faster Backup and Restore 

  • Bleach Maintenance Support – Compatible with the GSD Bleach Kit (Cat # SHW-20)  

  • Optional Text and Email Notifications for Errors 

 The AIX1000® 2.1 software is fully compatible with:  

  • AIX1000® RPR Reagent Kit (Cat # GSD01-1600)  

  • AIX1000® RPR Reagent Bulk Kit (Cat # GSD34-1600-R)  

  • GSD Bleach Kit (Cat # SHW-20)  

  • GSD RPR Diluent (Cat # GSD01-1600-DIL)  

Gold Standard Diagnostics continues to lead innovation in automated RPR testing, delivering precision, speed, and reliability to clinical laboratories worldwide.  

For more information, email gsd.sales@us.goldstandarddiagnostics.com or contact your GSD representative. 

For media inquiries, please contact:

Sarah Siegel, Marketing Communications

sarah.siegel@us.goldstandarddiagnostics.com